Active substances
Dextrose + Lidocaine
- SFDA 1
- Health Canada 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| 0.4% LIDOCAINE HCL AND 5% DEXTROSE IV infusion USP | 5,0.4 %,% | Solution · Intravenous use | 1 Bag | SAR 35.00 | Generic · Prescription | Pharmaceutical Solution Industries (PSI) | Valid |
Indications — CHI Daman Drug Formulary
PAIN MANAGEMENT IN CANCER PATIENTS; POSTOPERATIVE PAIN; RENAL AND URETERIC STONES
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| 0.4% LIDOCAINE HYDROCHLORIDE AND 5% DEXTROSE INJECTION | 00828602 | 50 MG / ML; 4 MG / ML | SOLUTION · INTRAVENOUS | BAXTER CORPORATION |
Components
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.